Quantcast

Latest Multiple myeloma Stories

2014-06-24 12:28:21

WILLIAMSBURG, Va., June 24, 2014 /PRNewswire/ -- The Snow Companies has been named a winner in the 35th Annual Telly Awards. The video entitled, "Multiple Myeloma in the African American Community" received a bronze award in the Non-Broadcast Health and Wellness category. Logo - http://photos.prnewswire.com/prnh/20140623/120706 "We are incredibly proud to be honored in this way," said Tyler James, Snow Companies' Vice President of Video Production. "At Snow, real patients share...

2014-06-11 12:28:56

Marketing Strategies That Educate Payers and Prescribers on Key Benefits of New Drugs Will Maximize Rapid Formulary Inclusion, According to Findings from Decision Resources Group BURLINGTON, Mass., June 11, 2014 /PRNewswire/ -- Decision Resources Group finds that regimens based on Janssen's Velcade are the most commonly prescribed treatments for first-line multiple myeloma (MM), according to surveyed hematological oncologists from France, Germany, Italy and Spain. The exception is the United...

2014-06-09 12:26:41

Public Healthcare Systems in Brazil and Mexico Cover Targeted Therapies but with Indication-Specific Restrictions, According to Findings from Decision Resources Group BURLINGTON, Mass., June 9, 2014 /PRNewswire/ -- Decision Resources Group finds that targeted therapies such as MabThera (rituximab) for non-Hodgkin's lymphoma (NHL) and Velcade (bortezomib) for multiple myeloma (MM) enjoy extensive but incomplete coverage in Brazil and Mexico through complex mechanisms. To obtain reimbursement,...

2014-06-02 08:32:06

Results show adding LBH589 to bortezomib and dexamethasone significantly improved PFS by 37%, meeting Phase III study primary endpoint1 EAST HANOVER, N.J., June 2, 2014 /PRNewswire/ -- Novartis today presented results from a pivotal Phase III trial showing a 37% improvement in progression-free survival (PFS) when using the investigational compound LBH589 (panobinostat) in combination with bortezomib[*] and dexamethasone compared to treatment with the same regimen with placebo in patients with...

2014-05-27 16:25:20

-Files patents on markers- TEL AVIV, Israel, May 27, 2014 /PRNewswire/ -- BioLight Life Sciences Investments Ltd. (OTC: BLGTY, TASE: BOLT), a firm that invests in, manages and commercializes biomedical innovations grouped into clusters around defined medical conditions, announced today that Micromedic Technologies (TASE: MCTC), BioLight's cancer diagnostic cluster company, has identified several new genetic markers with high potential to predict necrosis of the jawbone in multiple...

2014-05-19 08:29:00

WHITE PLAINS, N.Y., May 19, 2014 /PRNewswire-USNewswire/ -- Foundation Beyond Belief (FBB), a team of atheists, humanists and religious allies, just completed their second year with The Leukemia & Lymphoma Society's (LLS) Light The Night® fundraising campaign. FBB is a national partner in support of LLS's mission to find cures and ensure access to treatments for patients with blood cancers. As a Special Friend of Light The Night, FBB has raised $930,000 to date. In their first...

A Megadose Of The Measles Virus Kills Woman's Cancer In Early Trial
2014-05-15 11:15:31

Brett Smith for redOrbit.com - Your Universe Online In an early stage, proof-of-principle trial, researchers from the Mayo Clinic have demonstrated that a modified version of the measles virus is capable of destroying cancerous cells while leaving normal healthy tissue intact, according to a new report in Mayo Clinic Proceedings. In the trial, two patients with multiple myeloma were injected with a single massive dose of a genetically-engineered measles virus – enough to inoculate 10...

2014-04-07 08:29:25

CALGARY, April 7, 2014 /PRNewswire/ - Oncolytics Biotech Inc. ("Oncolytics") (TSX:ONC) (NASDAQ:ONCY) today announced that research collaborators will make two poster presentations at the American Association for Cancer Research 2014 Annual Meeting. The Meeting is being held from April 6(th) to 9(th), 2014 in San Diego, CA. "The data presented by these collaborators is contributing to our evolving understanding of how REOLSYIN(®) works, what biomarkers may be predictive of improved...

2014-03-27 08:35:29

DUBLIN, Mar. 27, 2014 /PRNewswire/ -- Research and Markets ( http://www.researchandmarkets.com/research/48gc9x/therapeutic_class ) has announced the addition of the "Therapeutic Class Overview: Treating Refractory Hematological Malignancies" report to their offering. (Logo: http://photos.prnewswire.com/prnh/20130307/600769) Targeting unmet needs in the treatment of cancer/ hematological malignancies through innovative drug development strategies have witnessed favorable...

2014-03-26 08:22:56

DUBLIN, Mar. 26, 2014 /PRNewswire/ -- Research and Markets ( http://www.researchandmarkets.com/research/lnx8jm/treating ) has announced the addition of the "Concise Analysis on Treating Refractory Hematological Malignancies for Multiple Myeloma" report to their offering. (Logo: http://photos.prnewswire.com/prnh/20130307/600769) "Concise Analysis on Treating Refractory Hematological Malignancies for Multiple Myeloma", provides an overview of the therapies for Multiple Myeloma (Newly...


Word of the Day
call-note
  • The call or cry of a bird or other animal to its mate or its young.
'Call-note' is newer than 'bird-call,' which originally referred to 'an instrument for imitating the note of birds' but now also refers to 'the song or cry of a bird.'
Related